

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 43/40, 43/42, 43/90	A1	(11) International Publication Number: WO 98/18326 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/19385 (22) International Filing Date: 27 October 1997 (27.10.97) (30) Priority Data: 60/029,214 28 October 1996 (28.10.96) US (71) Applicant: DEPARTMENT OF THE ARMY, U.S. GOVERNMENT [US/US]; 504 Scott Street, Fort Detrick, MD 21702-5012 (US). (72) Inventors: ELLIS, William, Y.; 14901 Kalmia Drive, Lauren, MD 20702 (US). KUNIN, Calvin, M.; 2447 Coventry Road, Columbus, OH 43221 (US). (74) Agents: HENDRICKS, Glenna et al.; P.O. Box 2509, Fairfax, VA 22031-2509 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC-RESISTANT INFECTIONS (57) Abstract <p>Compounds having antimicrobial activity are of the formula: A-B-N-Z(n) wherein N is a quinolyl, pyridyl or benzoquinolyl rings substituted at the carbon opposite the nitrogen on the nitrogen-containing ring by B-A wherein B is a carbon (C') bound to an oxygen, (=O, OH, Oalk, OCOalk, OCOaryl, OCOphenyl alkyl, or an oxygen in a cyclic moiety wherein aryl is phenyl or naphthyl and alkyl has 1-4 carbons and may be substituted hydroxy, or with 1-2 halo atoms) and wherein said carbon C' is also bound to a saturated carbon which is bond directly to a nitrogen-containing saturated chain or nitrogen-containing saturated ring system (for example, piperidinyl or quinuclidinyl ring systems), wherein any saturated ring system may be substituted with alkyl, alkenyl, halo, alkoxy or haloalkyl moieties of 1-5 carbons or with phenyl, phenoxy, phenylalkyl, phenylalkoxy, carboxy or carbonyl groups, wherein the carboxy or carbonyl groups, including keto or ester moieties with alkyl groups of 1-4 carbons, alkenyl groups of 2-5 carbons or phenylalkyl wherein the alkyl is of 1-3 carbons. Z is R_{1(m)} and/or R_{2(n)} wherein at least one of R₁ and R₂ is an electron-rich substituent and m and n may be 1-4 and wherein R₁ and/or R₂ may be alkyl, alkoxy, aryl, aryloxy, aryloxyalkyl, amino, aminoalkyl, alkylaminoalkyl, arylamino, alkenyl, arylalkenyl, arylalkylaminoalkyl, carboxyalkyl, hydroxy, halo, alkenyl, alkenyloxy, herein any alkyl has 1-8 carbons, alkenyl has 2-8 carbons, halo is chloro, fluoro or bromo and aryl is a ring system of 1-3 rings. Compounds are effective against both gram negative and gram positive organisms and against fungi.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC-RESISTANT INFECTIONS

Field of the Invention:

This invention relates to the treatment of antibiotic-resistant infections, including particularly infections caused by bacteria, Mycobacteria and fungi. A preferred group of compositions of the invention contain as active agents compounds containing pyridyl, quinolyl or benzoquinolyl ring systems substituted on the nitrogen-containing ring at the carbon opposite the nitrogen by a carbon bound to an oxygen which is also bound to a nitrogen through a saturated carbon or carbon chain, or, in the case of the pyridyl ring system, the substituent at the 4 position of the pyridyl ring may be an alkyl which may be substituted with halo, hydroxy, alkoxy, amino or alkylamino.

Background of the Invention:

The benefit from use of antibiotics as a means of treating infections has been increasingly compromised by the development of resistant strains of microorganisms. Most of the new drugs are derivatives of older compounds. It is necessary to develop new agents that will respond to the current needs for medicinals that will effectively control pathogenic microbial populations that are resistant to antibiotics.

Mefloquine is quinolyl compound having two trifluoromethyl groups attached to the quinolyl ring. This compound has been used to treat malaria. It has also been found to have some activity against bacterial pathogens in vitro.

Summary of the Invention:

This invention comprises compositions containing as active agents compounds which have pyridyl or quinolyl ring systems (including benzoquinolyl ring systems) substituted at the carbon opposite the nitrogen by a carbon bound directly to an oxygen and to a nitrogen through a saturated carbon or carbon chain or, in the case of pyridyl, an alkyl, alkenyl, alkyloxy, alkenyloxy, amino or alkylamino group wherein alkyl has 1-6

carbons, alkenyl has 2-6 carbons, wherein said alkyl or alkenyl groups may, optionally, have amino, hydroxy or halo substituents. Preferred compounds of the invention are those wherein the quinolyl ring system has at least one electron-rich substituent on the quinolyl ring system, including, for example, halo, phenyl, hydroxy, alkoxy or trihalomethyl substituents and the substituent at the carbon directly opposite the nitrogen atom is of the structure -CHOZX wherein Z may be a second bond to the oxygen or may be carboxyl, ether or ester moiety wherein the ether or ester moiety may be alkyl of 1-8 carbons, phenyl, phenylalkyl wherein the alkyl moiety consists of 1-4 carbons and wherein any said alkyl or phenyl group may, additionally, be substituted with hydroxy, alkyl of 1-2 carbons, alkenyl of 2-3 carbons, halo, amino, or alkyl amino group, X is $\text{CH}_2\text{N}((\text{CH}_2)_n(\text{CH}_3)_m)$ wherein n is ≤ 5 , m is 1 or 2 with the proviso that when m is 2, n is ≤ 3 , or X may be $\text{CH}_2\text{N}(\text{CH}_2)_q$ wherein q may be up to 10, which is cyclized and may have up to 4 bridge carbons or X is a saturated six-member nitrogen containing ring which may be substituted, wherein the piperidinyl moiety is bound through the carbon at the 2 position of the ring to the CHOZ through a carbon atom. The six member ring may have 1-4 bridge carbons to produce complex ring systems such as quinuclidinyl ring systems.

The active agents are useful for treating patients suffering from infections including gram positive bacteria, gram negative bacteria, fungi and mycobacterium. They are effective against strains which have shown resistance to other antimicrobial agents.


Detailed Description of the invention:

It has been found that compositions of the following formula: $\text{A-B-N-Z}(n)$ wherein N is a quinolyl, pyridyl or benzoquinolyl rings substituted at the carbon opposite the nitrogen on the nitrogen-containing ring by B-A wherein B is a carbon (C') bound to an oxygen, (=O, OH, Oalk, OCOalk, OCOaryl, OCophenyl alkyl, or an oxygen in a cyclic moiety wherein aryl is phenyl or naphthyl and alkyl has 1-4 carbons and may be substituted hydroxy, or with 1-2 halo


atoms) and wherein said carbon C' is also bound to a saturated carbon which is bond directly to a nitrogen-containing saturated chain or nitrogen-containing saturated ring system (for example, piperidinyl or quinuclidinyl ring systems),
5 wherein any saturated ring system may be substituted with alkyl, alkenyl, halo, alkoxy or haloalkyl moieties of 1-5 carbons or with phenyl, phenoxy, phenylalkyl, phenylalkoxy, carboxy or carbonyl groups, wherein the carboxy or carbonyl groups, including keto or ester moieties with alkyl groups of
10 1-4 carbons, alkenyl groups of 2-5 carbons or phenylalkyl wherein the alkyl is of 1-3 carbons. Z is $R_{1(m)}$ and/or $R_{2(n)}$ wherein at least one of R_1 and R_2 is an electron-rich substituent and m and n may be 1-4 and wherein R_1 and/or R_2 may be alkyl, alkoxy, aryl, aryloxy, aryloxyalkyl, amino, amino-
15 alkyl, alkylaminoalkyl, arylamino, alkenyl, arylalkenyl, arylalkylaminoalkyl, carboxyalkyl, hydroxy, halo, alkenyl, alkenyl-oxy, herein any alkyl has 1-8 carbons, alkenyl has 2-8 carbons, halo is chloro, fluoro or bromo and aryl is a ring system of 1-3 rings. Preferred electron-rich substituents are chosen from
20 moieties containing unsaturated ring systems (such as phenyl, phenoxy and naphthyl), halo (preferably chloro, fluoro), trihalomethyl, alkoxy, alkenyloxy, alkylamino and aminoalkyl-amino groups wherein any alkyl has 1-8 carbons. However, when N is quinolyl, if the 2 position on the quinolyl ring is
25 substituted with trihalomethyl and the 8 position is substituted with trihalomethyl or phenyl, the 6 or 7 position on the ring system must be further substituted with an electron-rich substituent such as halo or alkoxy. The preferred compounds of the invention require specifically a large substituent such
30 as phenyl, phenoxy, naphthyl, trihalomethyl (particularly trifluoromethyl) or quinuclidinyl groups at the 2 position on the ring system. Any alkyl or aryl moiety may further be substituted with halo, hydroxy, amino, alkylamino, alkylamino groups having 1-4 carbons or alkenyl, alkenylamino of 2-4
35 carbons.

When N is a pyridyl ring, the 2 and 6 positions of the pyridyl ring must be substituted with aryl groups wherein aryl



is phenyl or naphthyl. Compounds may be made by usual means. The following schemes are appropriate:



Cinchoninic Acid by Doebner Reaction



Particularly preferred compounds are of the formula:





Formula I

Formula II

wherein q is 1-3, and, in $N(\text{alkyl})_{(1 \text{ or } 2)}$, alkyl is of 1-8 carbons which may be substituted with halo or alkoxy and R_5 is H or alkyl of 1-4 carbons and, in formula II, wherein at least 1 of R_1 or R_2 is halo, haloalkyl, dihaloalkyl, trihaloalkyl or alkoxy.

or compounds of the formula:



Formula III

Formula IV

wherein R_5 is H or alkoxy, J is a saturated nitrogen containing ring attached at the 2 position of ring J which may be substituted with halo or alkoxy and, in Formula IV, at least 1 of R_1 is halo, haloalkyl, dihaloalkyl, trihaloalkyl or alkoxy.

In compounds of formula I and II, the dialkyl compounds are active against micobacteriam, but not against gram negative organisms or bacteria. Hence, for broad spectrum activity, the compounds of wherein, in $N(\text{alkyl})_{(1)}$, are preferred.

Materials and Methods

Active agents of the invention were tested for activity

against several infectious organisms. Testing for inhibitory effect against antibiotic-resistant organisms was accomplished in the following manner:

Media:

5 The strains were streaked on blood agar plates (trypticase soy broth containing 5% sheep cells). A single colony was isolated and grown in Mueller-Hinton Broth (MHB) as recommended by the national Committee for Clinical Laboratory Standards for rapidly growing bacteria. Candida species and related fungi
10 were isolated in a similar manner on brain-heart infusion agar (BHI).

Susceptibility tests:

15 The antibiotic susceptibility profile of each strain was determined using standard microtiter dilution plates obtained from the Clinical Microbiology Laboratory at Ohio State University Hospitals. The Inocula were prepared by suspending a 4 hour log phase growth in MHB visually equal in turbidity of an 0.5 McFarland standard. Inocula were further diluted and added to microdilution trays to achieve a final density of
20 approximately 1×10^5 CFU/ml. The trays were incubated for 16 to 20 hours at 35°C. The highest dilution at which wells remained clear was considered to be the minimum inhibitory concentration (MIC).

25 The MIC and minimum bacterial concentration (MBC) of the strains to the active agents were determined by two-fold dilutions in Mueller-Hinton broth. Susceptibility tests for ATCC-obtained microorganisms and clinical isolates of gram positive bacteria including methicillin-susceptible and resistant Staphylococci, Streptococci, Pneumococci and gram
30 negative bacteria, including Enterobacteriaceae, Pseudomonas, Hemophilus and Neisseria, were performed in microtiter plates as described above. The MIC and MBC were determined after 48 hours incubation at 35 - 37°C. A sample of 0.01 ml was taken from each clear well at the MIC end-point and streaked on trypticase soy agar plates. After 24 hours incubation, the number
35 of colonies was counted. The amount of the agent required to kill 99.9% of the bacterial inoculum was determined as the MBC.

Susceptibility tests for ATCC isolates of *Candida* and other fungi were performed in BHI broth according to the NCCLS method. Two ml of MHB containing serial dilutions of the agents compounds were added to 13 X 100 mm tubes. An inoculum of 0.1 ml (prepared as described above) was then added to each tube. The final inoculum was approximately 1×10^{-3} to 1×10^{-5} CFU/ml. The tubes were incubated at 35°C in ambient air and read at 24 hours. The highest dilution at which the tubes remained clear was considered to be the MIC.

The MBC was determined as follows: After 48 hours incubation, tubes without visible growth were vortexed. A sample of 0.01 ml was taken from each tube and streaked on trypticase soy agar plates. After 24 hours, incubation, the number of colonies was counted. The amount of agent required to kill 99.9% of bacterial inoculum in the inoculum was determined as the MBC. Susceptibility tests for *Mycobacteria* were performed according to standard methods at the national Institutes of Health.

Compounds of the invention were dissolved in 1 ml of methanol and stored in aliquots at -70°C. They were diluted in Mueller-Hinton broth for final screening. Compositions were tested in 0.1 ml volumes by serial dilution in microtiter plates against *Staphylococcus aureus* methicillin-sensitive ATCC 29213 and the methicillin-resistant wild type T67738, as described above. The T67738 was resistant to most antimicrobial drugs, including ciprofloxacin.

The most active compounds were studied further by time and dose-related killing curve analysis using large inocula (1×10^7 CFU/ml).

The lipid solubility of these compounds should permit the drugs to enter into cells and the central nervous system. The compounds would also be absorbed orally.

The dosage and method of administration will depend on the location of the infection, the condition of the patient and the availability of professional supervision. Methods of administration include parenteral, oral, buccal, nasal or endotracheal routes. The active agents may be administered as sprays. For

nasal administration, the active agent may be delivered as a powder that is snorted. Inclusion complexes such as cyclodextrin inclusion complexes are appropriate compositions and would be particularly useful for buccal administration of these active agents.

The compounds of the invention may also be administered topically by any means, including by rectal route. Suppositories, solutions for use as retention enemas, and creams or jellies are appropriate carriers for use in rectal administration.

Compounds of the invention may be applied to the skin or mucosa, including the vaginal mucosa, using creams, jellies, suppositories, or solutions. The active agents of the invention may be delivered directly to the epithelial tissue topically. During surgery example of such use could involve the application of compositions containing the active agents of the invention to the exposed tissue and prosthetic devices.

The compositions could be given by aerosol into the trachea or administered in mist along with other agents used in respiration therapy.

The compositions of the invention may also be used prophylactically to protect from infection by pathogenic organisms.

Dosage forms containing 25 to 1000 mg for administration by mouth are appropriate.

The concentration required to provide benefit was studied. The results may be seen in Table I

TABLE I

Active Agent:				Effective Concentration ($\mu\text{g/ml}$)		
N	B	A	Z	S. aureous		
				Sens.	Resist.	Mycobacteria
quin* (#5801)	C=O	$(\text{CH}_2)_4\text{CHCH}_3\text{NH}_2$	2 phenyl, 7 Cl		6.25	
quin (#6006, HCl salt)	CHOH piperidinyl ⁽ⁱ⁾		2 phenyl, 8 Cl	3.13	6.25	
quin (#7555, phosphate)	CHOH piperidinyl	$2 \text{ C}_6\text{H}_9\text{HN}$		6.25	6.25	
quin (#7929)	CHOH piperidinyl	2 (4 Cl phenyl)		6.25	6.25	
quin (#7930)	CHOH piperidinyl	2 phenyl, 6,8 Cl		<0.8	1.6	2
quin (#7936)	CHOH piperidinyl	2 (4 chlorphenyl) 6,8 dichloro		<0.8	<0.8	
quin (#7939)	CHOH piperidinyl	2 phenylethenyl		3.13	6.25	
quin CHOSi(CH ₃) ₃	piperidinyl	2 phenylethenyl		3.13	6.25	
quin (#117110)	CHOH piperidinyl	2 (4 chlorphenyl)amino 6,8 dimethyl		<0.8	<0.8	

* = quinolinyl (i) the piperidinyl is bound to the carbon CHOH at the 2 position unless stated otherwise

TABLE I, page 2

<u>Active Agent:</u>				<u>Effective Concentration (μg/ml)</u>		
N	B	A	Z	<u>S. aureus</u>		
				<u>Sens.</u>	<u>Resist.</u>	<u>Mycobacteria</u>
quin (#148987)	CHOH piperidinyl	2 (4 chlorophenoxy)	6 chloro	3.13	6.25	
quin (#159314, HCl salt)	CHOH piperidinyl	2,8 CF ₃ , 6 methoxy		6.25	3.13	
quin (#166391)	CHOH piperidinyl	2 quinuclidinyl	6,8 dichloro	<0.8	<0.8	1
quin (#169446)	AB=	2 phenyl				
		6,8 dichloro		1.6	1.6	2
quin (#211923, HCl salt)	CHOH piperidinyl	2 (4-phenylphenyl)		<0.8	<0.8	2
quin (#259398)	CHOH piperidinyl	2 (3,4-dichlorophenyl)	6 methoxy	1.56	1.56	
quin (#112312, oxide)	CHOH 3 ethyl-quinuclidinyl	6 methoxy		1.56	1.56	128
benzoquin** (#7333)	CHOH piperidinyl	2 phenyl		1.56	1.56	
benzoquin (#7573)	CHOH piperidinyl	2 (4 Cl-phenyl)		0.8	0.8	0.5

** Benzoquinoline

Table I, page 3

<u>Active Agent:</u>				<u>Effective Concentration ($\mu\text{g/ml}$)</u>	
N	B	A	Z	<u>S. aureus</u>	<u>Mycobacteria</u>
				<u>Sens.</u>	<u>Resist.</u>
benzoquin	CHOH	piperidinyl	7,8 dimethoxy	1.56	1.56
(#94413)					
benzoquin	CHOH	piperidinyl	2 CF ₃	3.0	
(#100305)					
pyridyl	CHOH	CH ₂ N(C ₂ H ₅) ₂	2,5 di(4-Cl-phenyl)	3.0	
(#142072)					
pyridyl	CHOH	piperidinyl	2,5 di(4-Cl-phenyl)	1.56	0.5
(#144809)					
pyridyl	CHOH	quinuclidinyl	2,5 di(4-Cl-phenyl)	1.5	0.5
(#148757, HCl salt)					
pyridyl	CHOH	CH ₂ N(CH ₃) ₂	2,5 di(4-Cl-phenyl)	3.0	
(#150089)					
pyridyl	CHOH	CH ₂ N(CH ₃ H ₉)	2,5 di(4-CF ₃ -phenyl)	1.56	
(#151312, HCl salt)					
pyridyl	CHOH	CH ₂ N(CH ₃)(C ₆ H ₉)	2,5 di(4-Cl-phenyl)	3.0	
(#153133, HCl salt)					
pyridyl	CHOH	CH ₂ NHCH(C ₃ H ₇) ₂	2,5 di(4-Cl-phenyl)	3.0	
(#153136, HCl salt)					
pyridyl	CHOH	piperidinyl	2,5 di(4-CF ₃ -phenyl)	1.5/3.0	0.5
(#153141, HCl salt)					

Table I, page 4

<u>Active Agent:</u>			<u>Effective Concentration ($\mu\text{g/ml}$)</u>	
N	B	A	<u>S. aureus</u>	<u>Resist.</u> <u>Mycobacteria</u>
pyridyl (#158483, HCl salt)	CHOH $\text{CH}_2\text{NHC}_5\text{H}_{11}$ (#158483, HCl salt)	2,5 di(4- CF_3 -phenyl)	6.2	
pyridyl (#171874, HCl salt)	CHOH $\text{CH}_2\text{NHCH}(\text{CH}_2\text{H}_5)(\text{CH}_3)$ (#171874, HCl salt)	2,5 di(4- CF_3 -phenyl)	3.0	
pyridyl (#171878, HCl salt)	CHOH $\text{CH}_2\text{NH}(\text{CH}_2\text{H}_5)$ (#171878, HCl salt)	2,5 di(4- CF_3 -phenyl)	3.0	
pyridyl (#172938, HCl salt)	CHOH $\text{CH}_2\text{NH}(\text{CH}_3\text{H}_7)$ (#172938, HCl salt)	2,5 di(4- CF_3 -phenyl)	3.0	
pyridyl	CHOH $\text{CH}_2\text{NH}(\text{CH}_4\text{H}_9)$	2-(4-Cl-phenyl), 5 naphthyl	3.0	

Example 1:

Capsules of a formulation of active agent designated #112312 for oral administration are prepared by containing 250 mg. of the active agent, 100 mg. starch, and 5 mg. magnesium stearate. The capsules are administered daily or twice a day to achieve a daily dosage of 500 mg. per day.

Example 2:

A preparation for application to the skin or mucosa may be prepared in the following manner:

Ingredient	%w/w
Compound #166391	15.0%
glyceryl monostearate	3.0%
Petrolatum	83.5%

Example 3:

A formulation for administration as a retention enema may be formulated in the following manner:

Ingredient	w/w %
Compound #211923	15%
Propylene glycol	85%

When the active agent is administered to the mucosa of the oral cavity, it may be administered as a buccal tablet or spray for use in the oral-pharyngeal cavity and the nasal cavities.

Example 4

To 15 ml of phosphate buffered saline is added 3 mg of compound #7573. The composition is placed in a bottle having a stopper with a smooth glass rod extending into the solution. The composition is applied to boils using the smooth glass rod as an applicator. The composition may also be administered as a spray from a bottle with an atomizer.

Example 5:

To a 4 X 4 inch bandage having a smooth surface on one side there is applied to the smooth surface .02 ml of the solution prepared as a 2 μ M solution of active agent designated # 7936 in PBS. The prepared bandage is then enclosed in a foil covering which is made air-tight. For

application, the bandage is unwrapped and is applied smooth side down on the wound.

Example 6:

A composition is prepared for use on the skin or mucosa in the following manner:

Ingredient	%w/w
Agent designated #144809	0.5%
propylene glycol	13.0%
Phosphate buffered saline	86.5%

When the active agent is administered to the mucosa of the oral cavity, it may be administered as a buccal tablet or spray for use in the oral-pharyngeal cavity and the nasal cavities.

Example 7:

A composition prepared as a gel for application to the skin:

Ingredient	%w/w
active agent designated #148757	0.5%
propylene glycol	10.0%
Polyethylene glycol	89.5%

Example 8:


A composition prepared for administration as a suppository:

Ingredient	%w/w
active agent #153141	0.5 mg
glyceryl monostearate	1.0 Gm
hydrogenated coconut oil	1.0 Gm
glyceryl monopalmitate	1.0 Gm

Compounds of the following structure showed particularly high activity:

CLAIMS

1. A method of treating a patient suffering from infection caused by bacteria, mycobacterium or fungi by administration to said patient of a composition containing as an active agent bacteria, mycobacterium or yeast growth-inhibiting effective amount of a compound of the formula:




wherein


N is a quinolyl, pyridyl or benzoquinolyl rings substituted at the carbon opposite the nitrogen on the nitrogen-containing ring by B-A wherein B is a carbon (C') bound to an oxygen, (=O, OH, Oalk, OCO-alk, OCOaryl, OCOphenyl alkyl, or an oxygen in a cyclic moiety wherein aryl is phenyl or naphthyl and alkyl has 1-4 carbons and may be substituted hydroxy, or with 1-2 halo atoms) and wherein said carbon C' is also bound to a saturated carbon which is bond directly to a nitrogen-containing saturated chain or nitrogen-containing saturated ring system (for example, piperidinyl or quinuclidinyl ring systems), wherein any saturated ring system may be substituted with alkyl, alkenyl, halo, alkoxy or haloalkyl moieties of 1-5 carbons or with phenyl, phenoxy, phenylalkyl, phenylalkoxy, carboxy or carbonyl groups, wherein the carboxy or carbonyl groups, including keto or ester moieties with alkyl groups of 1-4 carbons, alkenyl groups of 2-5 carbons or phenylalkyl wherein the alkyl is of 1-3 carbons or wherein Z is R₁ and/or R₂ wherein at least one of R₁ and R₂ is an electron-rich substituent and n may be 1-4 and wherein R₁ and/or R₂ may be alkyl, alkoxy, aryl, aryloxy, aryloxyalkyl, amino, amino-alkyl, alkyl-aminoalkyl, arylamino, alkenyl, aryl-alkenyl, arylalkylaminoalkyl, carboxyalkyl, hydroxy, halo, alkenyl, alkenyloxy, herein any alkyl has 1-8 carbons, alkenyl has 2-8 carbons, halo is chloro, fluoro or bromo and aryl is a ring system of

1-3 rings. Preferred electron-rich substituents are chosen from moieties containing unsaturated ring systems (such as phenyl, phenoxy and naphthyl), halo (preferably chloro, fluoro), trihalomethyl, alkoxy, alkenyloxy, alkylamino and aminoalkylamino groups wherein any alkyl has 1-8 carbons and wherein, when N is quinolyl, if the 2 position on the quinolyl ring is substituted with trihalomethyl and the 8 position is substituted with trihalomethyl or phenyl, the 6 or 7 position on the ring system must be further substituted with an electron-rich substituent such as halo or alkoxy.

2. A method of claim 1 wherein said active agent is of the formula:





Formula I



Formula II

wherein q is 1-3, and, in N(alkyl)_(1 or 2), alkyl is of 1-8 carbons which may be substituted with halo or alkoxy and R₅ is H or alkyl of 1-4 carbons and, in formula II, wherein at least 1 of R₁ or R₂ is halo, haloalkyl, dihaloalkyl, trihaloalkyl or alkoxy.

3. A method of claim 1 wherein said active agent is of the formula:



Formula III

Formula IV

wherein R_5 is H or alkoxy, J is a saturated nitrogen containing ring attached at the 2 position of ring J which may be substituted with halo or alkoxy and, in Formula IV, at least 1 of R_1 is halo, haloalkyl, dihaloalkyl, trihaloalkyl or alkoxy.

4. A method of claim 1 wherein the active agent is at least one of the compounds of table I.
5. A method of claim 1 wherein the active agent is at least one quinolyl compound of table I.
6. A method of claim 1 wherein the active agent is at least one benzoquinolyl compound of table I.
7. A method of claim 1 wherein the active agent is a pyridyl compound of table I.
8. A method of claim 2 having the substituent $N(alk)_1$.

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/US97/19385

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 43/40, 43/42, 43/90

US CL : 514/305, 311, 312, 314, 318, 350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/305, 311, 312, 314, 318, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
DIALOG

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US 5,580,882 A (ABRAMSKY ET AL.) 03 December 1996, col.2, lines 30-55 .	1-6,8
A	US 5,356,909 A (BAADER ET AL.) 18 October 1994 , col.2 , lines 5-65 .	1-4, 7-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 16 JANUARY 1998	Date of mailing of the international search report 17 FEB 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JYOTHSNA VENKAT Telephone No. (703) 308-2351